Nilatinib and capecitabine for HER2-positive stomach cancer with brain spread
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination pill (nilatinib maleate) and chemotherapy (capecitabine) for people with HER2-positive stomach or esophageal cancer that has spread to the brain. The goal is to see if this combo can shrink tumors and control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- You have been diagnosed with advanced stomach, esophageal, or junction cancer that is HER2-positive (a protein that fuels growth)
- Cancer has spread to your brain (shown on imaging)
- You have at least one measurable tumor (either in the brain or elsewhere) that hasn't been treated with radiation
- You have not taken a HER2-targeting pill that failed to work
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether neratinib plus capecitabine can slow or shrink breast cancer that has spread to the brain. It is for people whose cancer shows an “overactive HER2 signal” on a specific tumor test, even though their cancer is labeled HER2-negative.
This early-phase trial tests neratinib together with an antibody-drug to treat advanced HER2-positive gastro-esophageal (stomach/esophagus) cancer that can’t be removed by surgery. It’s for people whose cancer has progressed after at least one HER2-targeted treatment, aiming to shrink tumors and improve outcomes.
This trial tests a combination of two oral medications, pyrotinib and capecitabine, for people with HER2-positive breast cancer that has spread to the brain (active brain metastases) and has not responded to newer antibody-drug conjugates like Enhertu. The goal is to see if this drug pair can shrink brain tumors and help control the cancer without needing radiation first.
This trial tests a combination of targeted drugs (Disitamab Vedotin plus either Pyrotinib or Neratinib) for people with HER2-positive breast cancer that has spread to the brain. The goal is to see if this treatment can help shrink brain tumors or slow their growth.
This trial tests a three-drug combination (anlotinib, TQB2450, and nab-paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has progressed after prior treatment with a CLDN18.2-targeted regimen. The goal is to see if this new combination can shrink tumors and help patients live longer.
This trial tests a combination of two oral drugs—capecitabine (a chemotherapy pill) and pyrotinib (a targeted therapy)—for people with HER2-positive breast cancer that has spread. It is for those who have already had a recent type of targeted therapy called an ADC and are looking for a new treatment option that does not require a hospital visit.
Hear when a new Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.